Antibiotic Accountability: How Countries and Companies Perform

FT dashboard tracks responses to the growing threat of antimicrobial resistance

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections, according to a new analysis. The data — mapped by the FT from work led by a team at the University of Oxford and published in Lancet Planetary Health — estimates antibiotic consumption for 204 countries between 2000 and 2018. It shows a 46 per cent increase in global antibiotic usage, with a surge in nations including Sudan, India and Vietnam.

While many poorer countries have inadequate access to antibiotics, leading to unnecessary deaths through lack of adequate treatments, other middle and higher income countries are using volumes far beyond global norms. The study, based on a combination of prescription data and statistical modelling, shows that the highest rate of consumption in a single country — measured as a defined daily dose per 1,000 people per day — is in Greece, at nearly 45.9, compared with a global average of 14.3 and an average of 21.1 in Western Europe. There has also been a sharp rise in the Middle East, where antibiotics are often provided without prescriptions, which risks the development of bacterial strains resistant to drugs. These figures are included in an FT data dashboard designed to track the emerging trends in the “silent pandemic” of antimicrobial resistance, which causes hundreds of thousands of annual deaths. The dashboard aims to plot the growth in disease, medicine usage and efforts to respond by companies, governments and others. The Center for Disease Dynamics, Economics & Policy has also attempted to calculate the extent of antibiotic usage, and fresh studies are under way to link consumption to overall estimates of the burden of antimicrobial resistance.

Compared with the funding and level of research and development activity devoted to other disease categories, such as cancer, the pipeline is thin for new antibiotics, for diagnostics to help their targeted use, and for vaccines to prevent infection.

An annual benchmarking conducted by the Access to Medicine Foundation highlights variable efforts by both innovative and generic pharmaceutical companies in a range of activities — including research, surveillance and manufacturing — to tackle antimicrobial resistance.

An analysis by Farm Animal Investment Risk & Return — a think-tank designed in part to mobilise activist investors to reduce the extent of antibiotics in animals — highlights the variable response of the agro-food and restaurant sector.

Governments and other funders have stepped up support into research around the topic, but with a wide range of different approaches and levels of commitment, as illustrated by the Global AMR R&d Hub.

Broader efforts by countries to improve stewardship, through measures such as improved diagnosis and infection control, are also highly variable, as measured by the Global Coalition on Aging’s Global AMR Preparedness Index.

Source: Financial Times

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

What Old Age Might Be Like for Today’s 30-Year-Olds

Get ready for a new old age. With the U.S. fertility rate in a decadelong slump and the life expectancy of 65-year-old Americans approaching roughly 85, our aging nation is likely to grow older by midcentury, as the ratio of young to old continues to decline. The trend is likely to upend how our society is organized, making life very different for today’s 30-year-olds when they reach their 60s compared with life for 60-year-olds now.

World Population Reaches 8bn As It Grows Older

The world’s population reached 8bn people on Tuesday and will hit 9bn in 15 years as it experiences an unprecedented surge in the number of older people, according to the latest UN data. The global fertility rate has more than halved since the 1950s to 2.3 births per woman. With mortality also falling, the number of people aged 65 and over is expected to rise from 783mn in 2022 to 1bn by 2030 and reach 1.4bn by 2043, the UN population data revealed.

Global Coalition on Aging (GCOA) Launches Cross-Sector Alliance Committed to Health Innovation at High-Level Forum on The Silver Economy

Today, the Global Coalition on Aging (GCOA), along with cross-sector stakeholders representing patient advocacy, policy, industry, and academic communities, announced the launch of the Alliance for Health Innovation at the High-Level Forum on the Silver Economy in New York. The Alliance is dedicated to establishing the importance of innovation in achieving healthy aging and health equity through investments, policy reforms, and strategic partnerships.

Japan Must Face Up to Growing Danger of Drug-resistant Germs

In the wake of more than 6.4 million COVID-19 deaths worldwide and unprecedented economic destruction, the global community has no excuse to be caught unprepared for the next pandemic. Yet right now, a devastating parallel plague is already underway and worsening. Some years, it is killing well over 1 million people, according to medical journal The Lancet.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging.